Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06300177

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

A Randomized, Controlled, Double-blind, Double-simulated, Multicenter Phase III Clinical Study Evaluating D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure.

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions Non Small Cell Lung Cancer

Interventions D-1553 Tablet Docetaxel injection

Updated 5 times since 2024 Last updated: Apr 25, 2024 Started: Mar 28, 2024 Primary completion: Oct 31, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Non Small Cell Lung Cancer and is currently actively recruiting participants. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
May 2024 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Apr 2024 — May 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Mar 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Data source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anyang, China , Baoding, China , Beijing, China , Changchun, China , Changsha, China , Changzhi, China , Changzhou, China , Chengde, China , Chengdu, China , Chongqing, China and 46 more locations